Review: β-lactam alone was better than β-lactam plus aminoglycoside for cancer patients with neutropenia

Rotstein, Coleman
March 2003
ACP Journal Club;Mar/Apr2003, Vol. 138 Issue 2, p45
Academic Journal
Compares the effectiveness of β-lactam with combination therapy in febrile neutropenic patients with cancer. Background on neutropenia; Details of the randomized controlled trials used in the study; Importance of monotherapy in the treatment of cancer.


Related Articles

  • Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens for breast cancer. Gilbar, Peter; Sorour, Natacha; McPherson, Ian // Supportive Care in Cancer;Mar2015, Vol. 23 Issue 3, p619 

    A letter to the editor about the risk of febrile neutropenia (FN) with the docetaxel + cyclophosphamide (TC) and docetaxel + carboplatin + trastuzumab (TCH) regimens for breast cancer is presented.

  • Pre-Treatment CBC and the Prediction of Myelotoxicity. Ershler, William B. // Clinical Oncology Alert;Mar2009, Vol. 25 Issue 3, p19 

    NEUTROPENIA AND ASSOCIATED NEUTROPENIC EVENTS (NE), such as febrile neutropenia (FN) and treatment delays, are a major untoward effect of many chemotherapy regimens. In addition to the life-threatening aspect of infection in a myelosuppressed patient, there is also the issue of delays or...

  • Cefoperazone-sulbactam plus amikacin empirical therapy for febrile neutropenia in children with cancer. Bayram, İbrahim; Erbey, Fatih; Alabaz, Derya; Yilmaz, Sema; Tanyeli, Atila // Turkish Journal of Medical Sciences;2009, Vol. 39 Issue 4, p635 

    Aim: To determine the efficacy and safety of cefoperazone-sulbactam combined with amikacin in the treatment of febrile neutropenia in children with cancer. Materials and Methods: The study included 20 cancer cases with 26 febrile neutropenia (FEN) episodes. Patient selection criteria were...

  • Pegfilgrastim the best choice for FN prevention in the UK.  // PharmacoEconomics & Outcomes News;10/31/2009, Issue 590, p3 

    The article discusses research on the use of pegfilgrastim for primary prophylaxis against febrile neutropenia (FN) in British women suffering from breast cancer. The article discusses the study "The Economic Value of Primary prophylaxis Using Pegfilgrastim Compared With Filgrastim in Patients...

  • Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia. Ahn, Shin; Lee, Yoon-Seon; Chun, Yun-Hee; Kwon, In-Ho; Kim, Won; Lim, Kyung; Kim, Tae; Lee, Kyoo-Hyung // Supportive Care in Cancer;Aug2011, Vol. 19 Issue 8, p1151 

    Objectives: We intended to determine the predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia (FN). Methods: From January 1, 2007 to December 31, 2008, 396 episodes of FN in 346 cancer patients were retrospectively analyzed. Clinical and...

  • Efficacy and Tolerability of Extended-Interval Aminoglycoside Administration in Pediatric Patients. Kraus, D.M.; Pai, M.P.; Rodvold, K.A. // Pediatric Drugs;2002, Vol. 4 Issue 7, p469 

    Aminoglycosides are commonly used to treat serious Gram-negative infections in pediatric patients. An effort to improve the efficacy and tolerability of this antibiotic class has led to evaluation of extended-interval aminoglycoside administration (EIAA). EIAA is designed to achieve higher peak...

  • Cefepime.  // Reactions Weekly;11/13/2010, Issue 1327, p11 

    The article describes six case reports of men with hematological malignancies and mild renal impairment who developed neurotoxicity while receiving treatment with cefepime for febrile neutropenia, referencing a study published in the October 2010 issue of the journal "Antimicrobial Agents and...

  • Controlled Trials of Amphotericin B Lipid Complex. Boyle, James A. // Clinical Infectious Diseases;10/1/2000, Vol. 31 Issue 4, p1117 

    Focuses on the use of amphotericin B lipid complex (ABLC) and other lipid-associated formulations as therapy for febrile neutropenia. Treatment using Abelcet in patients who have developed intolerance to amphotericin B.

  • Outpatient Therapy for Febrile Neutropenia: Clinical and Economic Implications. de Lalla, Fausto // PharmacoEconomics;2003, Vol. 21 Issue 6, p397 

    Although febrile episodes in neutropenic patients remain a potentially life-threatening complication of anticancer chemotherapy, considerable progress has been achieved in understanding this issue. Febrile neutropenic patients represent a heterogeneous population that displays a very variable...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics